Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure

Drug Metabolism and Disposition

Volumn 42, Issue 1, 2014, Pages 28-32

  Court, Michael H ^a   Peter, Inga ^b   Hazarika, Suwagmani ^c   Vasiadi, Magdalini ^d   Greenblatt, David J ^c,d   Lee, William M ^e  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOCHROME P450 2E1; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; HERMES ANTIGEN; LIVER ENZYME; PARACETAMOL; SULFOTRANSFERASE 1A1;

ACUTE LIVER FAILURE; ALLELE; ARTICLE; BHMT1 GENE; CD44 GENE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYP2E1 GENE; CYP3A5 GENE; DRUG MEGADOSE; DRUG OVERDOSE; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; EXPLORATORY RESEARCH; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SULT1A1 GENE; UGT1A1 GENE; UGT1A6 GENE; UGT1A9 GENE; UGT2B15 GENE; VOLUNTEER;

ACETAMINOPHEN; ALLELES; ANTIGENS, CD44; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP3A; DRUG-INDUCED LIVER INJURY; GENOTYPE; HUMANS; LIVER FAILURE, ACUTE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84890716325     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053546     Document Type: Article

References (22)

1. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
2. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver micro-somes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006. (Pubitemid 33104971)
3. Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ, and Lee WM; Acute Liver Failure Study Group (2013) The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C.G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther 345:297-307.
4. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, and Greenblatt DJ (2004) UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656-665. (Pubitemid 38988911)
5. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, and Guillemette C (2004) Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515. (Pubitemid 39100002)
6. Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, and Guillemette C (2005) UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 42:448-457. (Pubitemid 41061098)
7. Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, Boorman GA, Russo MW, Sackler RS, and Harris SC, et al. (2009) Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 19: 1507-1515.
8. Hu Y, Hakkola J, Oscarson M, and Ingelman-Sundberg M (1999) Structural and functional characterization of the 59-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 263: 286-293. (Pubitemid 29467189)
9. Khandelwal N, James LP, Sanders C, Larson AM, and Lee WM; Acute Liver Failure Study Group (2011) Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 53:567-576.
10. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, and Court MH (2005) UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 59-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther 313:1331-1339. (Pubitemid 40727039)
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, and Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. (Pubitemid 32268418)
12. Laine JE, Auriola S, Pasanen M, and Juvonen RO (2009) Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 39:11-21.
13. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, and Shakil AO, et al.; Acute Liver Failure Study Group (2005) Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42:1364-1372. (Pubitemid 43260039)
14. Liu HH, Lu P, Guo Y, Farrell E, Zhang X, Zheng M, Bosano B, Zhang Z, Allard J, and Liao G, et al. (2010) An integrative genomic analysis identifies Bhmt2 as a diet-dependent genetic factor protecting against acetaminophen- induced liver toxicity. Genome Res 20:28-35.
15. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, and Hynan L, et al.; U.S. Acute Liver Failure Study Group (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947-954. (Pubitemid 35440240)
16. Patel M, Tang BK, and Kalow W (1992) Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics 2:38-45.
17. Rauchschwalbe SK, Zühlsdorf MT, Wensing G, and Kuhlmann J (2004) Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int J Clin Pharmacol Ther 42:73-77. (Pubitemid 38219917)
18. Schiødt FV, Rochling FA, Casey DL, and Lee WM (1997) Acetaminophen toxicity in an urban county hospital. N Engl J Med 337:1112-1117. (Pubitemid 27444101)
19. Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N, and Wu X (2002) Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 35:137-142. (Pubitemid 34136090)
20. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, and Harris SC (2006) Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296:87-93.
21. Yasar U, Greenblatt DJ, Guillemette C, and Court MH (2013) Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers. J Pharm Pharmacol 65:874-883.
22. Zhao L and Pickering G (2011) Paracetamol metabolism and related genetic differences. Drug Metab Rev 43:41-52.